SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-17-154971
Filing Date
2017-05-03
Accepted
2017-05-03 07:03:01
Documents
73
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d240610d10q.htm 10-Q 483932
2 EX-31.1 d240610dex311.htm EX-31.1 10181
3 EX-31.2 d240610dex312.htm EX-31.2 10226
4 EX-32.1 d240610dex321.htm EX-32.1 6812
  Complete submission text file 0001193125-17-154971.txt   3819212

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT vnda-20170331.xml EX-101.INS 601756
6 XBRL TAXONOMY EXTENSION SCHEMA vnda-20170331.xsd EX-101.SCH 56480
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vnda-20170331_cal.xml EX-101.CAL 70581
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20170331_def.xml EX-101.DEF 309753
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20170331_lab.xml EX-101.LAB 405157
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20170331_pre.xml EX-101.PRE 369391
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 17807114
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences